论文部分内容阅读
目的:观察加用帕罗西汀治疗慢性充血性心力衰竭伴抑郁的疗效及安全性。方法:纳入汉密尔顿抑郁量表(HAMD)评分>20分的慢性充血性心力衰竭患者共60名,随机分为对照组和治疗组,每组各30例。对照组给予常规抗心衰治疗,治疗组在此基础上加用帕罗西汀抗抑郁治疗。于入院时和接受药物治疗16周时采用HAMD量表进行评分;记录纽约心功能分级(NYHA)改善情况及超声心动图LVEF变化,并观察帕罗西汀使用过程中的不良反应。结果:治疗组HAMD评分、NYHA、LVEF改善优于对照组,有显著性差异(P<0.05),不良反应轻微。结论:帕罗西汀不仅能改善心衰伴抑郁患者的抑郁情况,还可以改善心功能状况,并具有良好的安全性。
Objective: To observe the efficacy and safety of paroxetine in the treatment of chronic congestive heart failure with depression. Methods: A total of 60 patients with chronic congestive heart failure with a Hamilton Depression Rating Scale (HAMD) score> 20 were randomly divided into control group and treatment group, 30 cases in each group. The control group was given routine anti-heart failure treatment, and the treatment group was treated with paroxetine anti-depression on the basis of this. The HAMD scale was used at admission and at the 16th week of drug treatment. The improvement of New York Heart Association (NYHA) and the change of echocardiography LVEF were recorded and the side effects of paroxetine were observed. Results: The improvement of HAMD score, NYHA and LVEF in the treatment group was better than that in the control group (P <0.05). The adverse reaction was mild. Conclusion: Paroxetine can not only improve depression in patients with heart failure and depression, but also improve cardiac function and have good safety.